# A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

> **NCT05866055** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 30 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-973
- **DRUG:** Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT05866055
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866055, "A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05866055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*